Teratogenic effects of antiepileptic drugs

The Lancet Neurology

Volumn 11, Issue 9, 2012, Pages 803-813

  Tomson, Torbjörn ^a   Battino, Dina ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; FOLIC ACID; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANTICONVULSANT THERAPY; AUTISM; BEHAVIOR DISORDER; CHILD BEHAVIOR; CLEFT FACE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONGENITAL MALFORMATION; DRUG SAFETY; EPILEPSY; FETAL ANTICONVULSANT SYNDROME; FETUS RISK; FETUS WASTAGE; HUMAN; HYPOSPADIAS; INTELLIGENCE QUOTIENT; INTRAUTERINE GROWTH RETARDATION; MICROCEPHALY; MONOTHERAPY; NEURAL TUBE DEFECT; POSTNATAL DEVELOPMENT; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SPONTANEOUS ABORTION; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84865135028     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70103-5     Document Type: Review

References (98)

1. Lenz W, Knapp K Thalidomide embryopathy. Arch Environ Health 1962, 5:100-105.
2. Meadow SR Anticonvulsant drugs and congenital abnormalities. Lancet 1968, 2:1296.
3. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008, 81:1-13.
4. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009, 73:133-141.
5. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001, 344:1132-1138.
6. Shorvon S, Tomson T Sudden unexpected death in epilepsy. Lancet 2011, 378:2028-2038.
7. Cantwell R, Clutton-Brock T, Cooper G, et al. Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011, 118(suppl 1):1-203.
8. Hiilesmaa VK, Bardy A, Teramo K Obstetric outcome in women with epilepsy. Am J Obstet Gynecol 1985, 152:499-504.
9. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006, 66:354-360. EURAP Study Group.
10. Adab N, Tudur SC, Vinten J, Williamson P, Winterbottom J Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev 2004, 3. CD004848.
11. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011, 96:643-647.
12. Tomson T, Perucca E, Battino D Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004, 45:1171-1175.
13. Kaplan PW, Norwitz ER, Ben-Menachem E, et al. Obstetric risks for women with epilepsy during pregnancy. Epilepsy Behav 2007, 11:283-291.
14. Thomas SV, Sindhu K, Ajaykumar B, Sulekha Devi PB, Sujamol J Maternal and obstetric outcome of women with epilepsy. Seizure 2009, 18:163-166.
15. Pittschieler S, Brezinka C, Jahn B, et al. Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. J Neurol 2008, 255:1926-1931.
16. Hvas CL, Henriksen TB, Ostergaard JR, Dam M Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. BJOG 2000, 107:896-902.
17. Battino D, Kaneko S, Andermann E, et al. Intrauterine growth in the offspring of epileptic women: a prospective multicenter study. Epilepsy Res 1999, 36:53-60.
18. Almgren M, Kallen B, Lavebratt C Population-based study of antiepileptic drug exposure in utero-influence on head circumference in newborns. Seizure 2009, 18:672-675.
19. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009, 50:2130-2139.
20. Wide K, Winbladh B, Tomson T, Kallen B Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years. Epilepsia 2000, 41:854-861.
21. Hanson JW, Smith DW Fetal hydantoin syndrome. Lancet 1976, 1:692.
22. Jones KL, Lacro RV, Johnson KA, Adams J Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989, 320:1661-1666.
23. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ The fetal valproate syndrome. Am J Med Genet 1984, 19:473-481.
24. Kini U, Adab N, Vinten J, Fryer A, Clayton-Smith J Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. Arch Dis Child Fetal Neonatal Ed 2006, 91:F90-F95.
25. Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005, 64:1874-1878.
26. Wide K, Winbladh B, Kallen B Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004, 93:174-176.
27. Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011, 76:1817-1823.
28. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006, 77:193-198.
29. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012, 78:1692-1699.
30. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011, 10:609-617.
31. Molgaard-Nielsen D, Hviid A Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011, 305:1996-2002.
32. Tomson T, Battino D, Perucca E Major birth defects after exposure to newer-generation antiepileptic drugs. JAMA 2011, 306:826-827.
33. Montouris A, Harden C, Albano J, Leppik I, Miller D. Incidence of congenital malformations in infants born to patients with epilepsy: a comparison of pregnancy registries and cohort study data. The 64th Annual Meeting of the American Academy of Neurology. New Orleans, FL, USA; April 21-28, 2012. Abstract 770.
34. Vajda FJ, Graham J, Hitchcock AA, O'Brien TJ, Lander CM, Eadie MJ Foetal malformations after exposure to antiepileptic drugs in utero assessed at birth and 12 months later: observations from the Australian Pregnancy Register. Acta Neurol Scand 2011, 124:9-12.
35. Thomas SV, Nair RR, Jose M, Sarma PS Risk of major congenital malformations in the offsprings of women with epilepsy is not related to family history. Epilepsy Res 2009, 83:52-57.
36. Tomson T, Battino D, Craig J, et al. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia 2010, 51:909-915.
37. Kondo T, Kaneko S, Amano Y, Egawa I Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996, 37:1242-1244.
38. Samrén EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999, 46:739-746.
39. Fonager K, Larsen H, Pedersen L, Sorensen HT Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol Scand 2000, 101:289-294.
40. Hvas CL, Henriksen TB, Ostergaard JR Birth weight in offspring of women with epilepsy. Epidemiol Rev 2000, 22:275-282.
41. Montouris G Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 2003, 4:310-317.
42. Kaaja E, Kaaja R, Hiilesmaa V Major malformations in offspring of women with epilepsy. Neurology 2003, 60:575-579.
43. Meischenguiser R, D'Giano CH, Ferraro SM Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004, 5:163-167.
44. Montouris G Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 2005, 21:693-701.
45. Long L, Helfant H A case series of clinical and developmental outcomes in the offspring of pregnant women taking levetiracetam monotherapy. Epilepsia 2006, 47(suppl 4):258.
46. Hunt S, Craig J, Russell A, et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2006, 67:1876-1879.
47. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008, 71:272-276.
48. Ornoy A, Zvi N, Arnon J, Wajnberg R, Shechtman S, Diav-Citrin O The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol 2008, 25:388-389.
49. ten Berg K, Samrén EB, van Oppen AC, Engelsman M, Lindhout D Levetiracetam use and pregnancy outcome. Reprod Toxicol 2005, 20:175-178.
50. French J, Edrich P, Cramer JA A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001, 47:77-90.
51. Mawer G, Briggs M, Baker GA, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010, 19:112-119.
52. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011, 68:1275-1281.
53. Vajda FJ, Hitchcock AA, Graham J, O'Brien TJ, Lander CM, Eadie MJ The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2009, 51:805-810.
54. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64:961-965.
55. Robert E, Guibaud P Maternal valproic acid and congenital neural tube defects. Lancet 1982, 2:937.
56. Lindhout D, Meinardi H Spina bifida and in-utero exposure to valproate. Lancet 1984, 2:396.
57. Kallen AJ Maternal carbamazepine and infant spina bifida. Reprod Toxicol 1994, 8:203-205.
58. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008, 70:2152-2158.
59. Hernandez Diaz R, Mittendorf R, Holmes L Comparative safety of topiramate during pregnancy. Birth Defects Res (Part A) 2010, 88:408.
60. Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?. Neurology 2008, 71:714-722.
61. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010, 362:2185-2193.
62. Jentink J, Dolk H, Loane MA, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010, 341:c6581.
63. Artama M, Isojarvi JI, Raitanen J, Auvinen A Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol 2004, 159:1057-1063.
64. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999, 40:1231-1236.
65. Dansky L, Wolfson C, Anderman E, Andermann F, Sherwin A A multivariate analysis of risk factors for major congenital malformations in offspring of epileptic women. Epilepsia 1989, 30:678.
66. Diav-Citrin O, Shechtman S, Arnon J, Ornoy A Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001, 57:321-324.
67. Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992, 42:75-82.
68. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000, 321:674-675.
69. Holmes LB, Wyszynski DF, Lieberman E The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004, 61:673-678.
70. Melchior JC, Svensmark O, Trolle D Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. Lancet 1967, 2:860-861.
71. Millar JH, Nevin NC Congenital malformations and anticonvulsant drugs. Lancet 1973, 1:328.
72. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997, 68:18-24.
73. Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992, 42:119-125.
74. Ornoy A, Cohen E Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996, 75:517-520.
75. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997, 38:981-990.
76. Viinikainen K, Heinonen S, Eriksson K, Kalviainen R Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006, 47:186-192.
77. Waters CH, Belai Y, Gott PS, Shen P, De Giorgio CM Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol 1994, 51:250-253.
78. Nicolai J, Vles JS, Aldenkamp AP Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: a critical review directed at structural study-bias. J Neurol Sci 2008, 271:1-14.
79. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
80. Meador KJ, Baker GA, Browning N, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011, 134:396-404.
81. Bromley RL, Mawer G, Love J, et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 2010, 51:2058-2065.
82. Thomas SV, Ajaykumar B, Sindhu K, Nair MK, George B, Sarma PS Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav 2008, 13:229-236.
83. Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011, 76:383-389.
84. Nadebaum C, Anderson VA, Vajda F, Reutens DC, Barton S, Wood AG Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 2011, 76:719-726.
85. Nadebaum C, Anderson V, Vajda F, Reutens D, Barton S, Wood A The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc 2011, 17:133-142.
86. Forsberg L, Wide K, Kallen B School performance at age 16 in children exposed to antiepileptic drugs in utero-a population-based study. Epilepsia 2011, 52:364-369.
87. Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976, 1:272-275.
88. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994, 271:767-770.
89. Wide K, Henning E, Tomson T, Winbladh B Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 2002, 91:409-414.
90. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004, 62:28-32.
91. Titze K, Koch S, Helge H, Lehmkuhl U, Rauh H, Steinhausen HC Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Dev Med Child Neurol 2008, 50:117-122.
92. Vinten J, Bromley RL, Taylor J, Adab N, Kini U, Baker GA The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav 2009, 14:197-201.
93. Bromley RL, Mawer G, Clayton-Smith J, Baker GA Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008, 71:1923-1924.
94. Christensen J. Prenatal valproate exposure and risk of autism-a population based study. American Epilepsy Society 65th Annual Meeting; Baltimore, MD, USA; Dec 2-6, 2011. Abstract B.09.
95. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs 2008, 22:325-334.
96. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999, 33:145-158.
97. Vajda FJ, Graham J, Roten A, Lander CM, O'Brien TJ, Eadie M Teratogenicity of the newer antiepileptic drugs-the Australian experience. J Clin Neurosci 2012, 19:57-59.
98. Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker GA Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005, 64:949-954.